Our results indicated that CAFs reduce the anticancer activity of anti-VEGF antibodies, whereas inhibiting CAF–cancer cell interaction potentiates the effect of antiangiogenic antibodies in a mouse model. The gene discussed is VEGFA; the disease is cancer.